Title |
Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity
|
---|---|
Published in |
Leukemia & Lymphoma, January 2012
|
DOI | 10.3109/10428194.2011.642302 |
Pubmed ID | |
Authors |
Steven Lane, Devinder Gill, Nigel A. J. McMillan, Nicholas Saunders, Rachel Murphy, Terrence Spurr, Colm Keane, Helen Mar Fan, Peter Mollee |
Abstract |
Elderly patients with acute myeloid leukemia (AML) have a poor prognosis. The authors examined the in vitro and clinical activity of the histone deacetylase inhibitor valproic acid (VA) combined with cytosine arabinoside (AraC) in elderly patients with AML unsuited to intensive therapy. For the in vitro studies, primary AML cells from 11 patients were treated with AraC and VA and analyzed for apoptosis, cytostatic effects, differentiation and acetyl histone H3 induction. VA (alone and with AraC) enhanced apoptosis and induced acetyl histone H3. VA inhibited cell proliferation. For the clinical trial, 15 patients were treated with VA and subcutaneous AraC and assessed for toxicity and response. No complete or partial remissions were achieved. In conclusion, VA has in vitro activity against AML and has additional activity with AraC. However, in this study, this combination demonstrated limited clinical activity in elderly patients with AML. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 11 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 2 | 18% |
Other | 1 | 9% |
Researcher | 1 | 9% |
Professor > Associate Professor | 1 | 9% |
Student > Postgraduate | 1 | 9% |
Other | 0 | 0% |
Unknown | 5 | 45% |
Readers by discipline | Count | As % |
---|---|---|
Psychology | 2 | 18% |
Agricultural and Biological Sciences | 1 | 9% |
Unknown | 8 | 73% |